Genelux
GNLXGNLX · Stock Price
Historical price data
Overview
Genelux is a clinical-stage biotech focused on developing oncolytic viral immunotherapies to treat cancer. Its mission is to leverage its proprietary CHOICE™ platform, built on the vaccinia virus backbone, to create therapies that deliver a full complement of tumor neoantigens and stimulate a potent, personalized immune response. The company's strategy centers on advancing its lead candidate, Olvi-Vec, through late-stage trials in ovarian cancer and other solid tumors, while pursuing strategic partnerships and leveraging in-house manufacturing capabilities to build a fully integrated therapeutics company.
Technology Platform
The CHOICE™ discovery platform is a proprietary system for generating oncolytic vaccinia virus (VACV) immunotherapies, featuring a library of over 500 engineered VACV strains armed with transgenes to enhance tumor selectivity, immune activation, and delivery versatility.
Pipeline
10| Drug | Indication | Stage | Watch |
|---|---|---|---|
| olvimulogene nanivacirepvec + Platinum chemotherapy: carbopl... | Platinum-resistant Ovarian Cancer | Phase 3 | |
| Olvimulogene nanivacirepvec + Platinum chemotherapy: carbopl... | Advanced Non-squamous Non-small-cell Lung Cancer | Phase 2 | |
| Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide | SCLC, Extensive Stage | Phase 1/2 | |
| GL-ONC1 | Peritoneal Carcinomatosis | Phase 1/2 | |
| GL-ONC1 alone, or in combination with chemotherapy with or w... | Ovarian Cancer | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
Genelux competes in the oncolytic virotherapy segment, differentiating itself through a focus on systemic intravenous delivery of a potent vaccinia virus. Key competitors include Replimune, PsiOxus, and the approved but locally delivered Imlygic (Amgen). Success hinges on demonstrating superior efficacy, particularly in overall survival, for disseminated cancers.
